期刊论文详细信息
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 卷:81
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled study
Article
Noe, Megan H.1  Wan, Marilyn T.1  Shin, Daniel B.1  Armstrong, April W.2  Duffin, Kristina Callis3  Fuxench, Zelma C. Chiesa1  Kalb, Robert E.4  Menter, Alan5  Simpson, Eric L.6  Takeshita, Junko1,7  Tyring, Stephen K.8  Van Voorhees, Abby S.9  Mehta, Nehal N.10  Gelfand, Joel M.1,7 
[1] Univ Penn, Dept Dermatol, Perelman Sch Med, Philadelphia, PA 19104 USA
[2] Univ Southern Calif, Keck Sch Med, Dept Dermatol, Los Angeles, CA USA
[3] Univ Utah, Dept Dermatol, Salt Lake City, UT USA
[4] SUNY Buffalo, Dept Dermatol, Williamsville, NY USA
[5] Baylor Univ, Med Ctr, Dept Dermatol, Dallas, TX USA
[6] Oregon Hlth & Sci Univ, Dept Dermatol, Portland, OR 97201 USA
[7] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA
[8] Univ Texas Dallas, Dept Dermatol, McGovern Med Sch, Dallas, TX USA
[9] Eastern Virginia Med Sch, Dept Dermatol, Norfolk, VA 23501 USA
[10] NHLBI, Cardiopulm Branch, Bldg 10, Bethesda, MD 20892 USA
关键词: adalimumab;    DLQI;    EQ5D;    patient-reported outcomes;    phototherapy;    psoriasis;    randomized controlled trials;   
DOI  :  10.1016/j.jaad.2019.05.080
来源: Elsevier
PDF
【 摘 要 】

Background: There are limited data about the impact of narrowband ultraviolet B phototherapy on patient-reported measures of health-related quality of life. Objective: To evaluate the impact of adalimumab and phototherapy on health-related quality of life. Methods: We examined patient-reported outcomes from a multicenter, randomized, placebo-controlled trial (ClinicalTrials. gov no. NCT01553058). The Dermatology Life Quality Index and EQ-5D-3L were evaluated every 4 weeks. Results: We enrolled 97 patients: 30.9% were female, mean age was 43.5 years (standard deviation, 14.0), and median Psoriasis Area and Severity Index score was 16.7 (interquartile range, 13.9-21.6). At week 12, patients being treated with adalimumab (odds ratio [OR], 2.88; 95% confidence interval [CI], 1.02-8.17) and phototherapy (OR, 8.83; 95% CI, 2.47-31.57) were more likely to achieve the minimal clinically important difference in the Dermatology Life Quality Index compared with those receiving placebo. There were higher odds of achieving the minimal clinically important difference for the EQ-5D-3L Index score when comparing phototherapy versus placebo (OR, 9.78; 95% CI, 2.99-31.95) and phototherapy versus adalimumab (OR, 4.07; 95% CI, 1.42-11.70). Limitations: Small sample size, secondary analysis, generalizability. Conclusion: Phototherapy and adalimumab both improve skin-related quality of life and overall health-related quality of life compared with placebo in patients with psoriasis; however, patients treated with phototherapy achieved more improvement in overall health-related quality of life compared with patients treated with adalimumab.

【 授权许可】

Free   

【 预 览 】
附件列表
Files Size Format View
10_1016_j_jaad_2019_05_080.pdf 394KB PDF download
  文献评价指标  
  下载次数:0次 浏览次数:0次